Advocate General of the CJEU: Stem cells from parthenotes are patentable

Dr. Franz-Josef Zimmer
Dr. Markus Grammel

25 September 2014

A discussion of the recent opinion of the Advocate General of the Court of Justice of the European Union (CJEU) in the stem cell case C-364/13.
Against the backdrop of an increasingly unfavorable European legal landscape for human stem cell patents (see LSIPR 2014, 1.3), in his recent Opinion in case C-364/13 the Advocate General (AG) Cruz Villalón of the Court of Justice of the European Union (CJEU) gives reason to believe that there is some light on the horizon for applicants seeking patent protection for stem cell-related inventions.

In the case in question, the CJEU is basically called on to decide whether human parthenotes might be regarded as embryos and therefore excluded from patentability under Article 6(2)(c) of Directive 98/44/EC (the Biotech Directive), which states that ‘uses of human embryos for industrial or commercial purposes’ shall be considered unpateentable. The AG says no, and recommends that human parthenotes do not fall under the term ‘human embryo’ of Article 6(2)(c), currently the most crucial obstacle to patentability for stem cell related inventions in Europe.

But what really is a parthenote, why does the CJEU consider the patentability of human parthenotes (again), and how is this relevant for the patentability of human stem cells?

Technical Background
A parthenote is an unfertilized ovum that has been induced to undergo cell divisions without being fertilized by a sperm cell. The process of an ovum developing into an embryo and potentially further into a viable being, without fertilization, is referred to as parthenogenesis, leading to a parthenote. While parthenotes of some species have the potential to develop to term, human parthenotes, at least according to current scientific knowledge, are incapable of developing into a viable human being, the reason being the lack of paternal DNA, without which an essential process called genomic imprinting cannot take place.

Importantly, however, human parthenotes may still serve as a source for pluripotent stem cells, i.e. stem cells that have the capacity to develop into a wide range of different cell types and tissues, which hold a lot of promise for the future treatment of various degenerative diseases.

Factual Background
In the case underlying the present opinion, International Stem Cell Corporation (ISC) filed two patent applications with the UK Intellectual Property Office (UK IPO) relating to human stem cells derived from parthenotes. The UK IPO refused both applications on the grounds that, by relating to human parthenotes, they involve the use of human embryos for industrial or commercial purposes excluded from patentability under Article 6(2)(c) of the Biotech Directive, thereby following a previous ruling of the CJEU in C-34/19 (the Brüstle case). In Brüstle the court had found that any human parthenote constitutes a ‘human embryo’ in the sense of Article 6(2)(c).

ISC appealed the decision of the UK IPO to the High Court of Justice of England and Wales, the referring court in the present case, and essentially argued that the CJEU in Brüstle subsumed human parthenotes under the term ‘human embryo’ only as far as they have the capability to develop into a viable human being. On the other hand, the Comptroller General of patents, representing the UK IPO, and the High Court believed that the Brüstle ruling was unclear in this regard, once more leading the High Court to request guidance and clarification from the CJEU on this matter.

The meaning of ‘commencing the process’
In the well-known and highly relevant Brüstle case the CJEU already had to decide what is encompassed by the term ‘human embryo’ of Article (6)(2)(c) of the Biotech Directive. In that decision, the CJEU held that
any non-fertilised human ovum whose division and further development have been stimulated by parthenogenesis constitute a ‘human embryo’.

While the CJEU’s statement might seem pretty clear on the face of it, it is important to consider that the court arrived at this decision mainly by arguing for a wide interpretation of the concept of ‘human embryo’ and that, just as an embryo that was created by fertilization of a human ovum, a human parthenote is

‘capable of commencing the process of development of a human being just as an embryo created by fertilisation of an ovum can do so’.

According to the Comptroller General and the High Court, it is the term ‘commencing the process’ that makes the Brüstle ruling ambiguous. Does ‘commencing the process’ mean that the parthenote has to possess the inherent capacity to develop into a viable human being, or does it merely refer to the initial steps in the process, independent of the actual potential to complete the process of development of a human being?

Moreover, the High Court noted that the factual foundation of the Brüstle decision no longer applies, that is, the CJEU in Brüstle ruled under the impression that human parthenotes actually have the capacity to develop into a viable human being, while current scientific evidence clearly supports - and this view is shared by all parties involved - that human parthenotes lack such capacity.

Therefore, the High Court considered it necessary to request further clarification on this matter from the CJEU and submitted the following question:

‘Are unfertilised human ova whose division and further development have been stimulated by parthenogenesis, and which, in contrast to fertilised ova, contain only pluripotent cells and are incapable of developing into human beings, included in the term “human embryos” in Article 6(2)(c) of Directive 98/44/EC on the legal protection of biotechnological inventions?’

The Advocate General

As suggested by the High Court, the AG finds that the Brüstle decision hinges on the interpretation of the term ‘capable of commencing’.

According to the AG, the CJEU erroneously established a functional equivalence between fertilized ova, non-fertilized ova subjected to nuclear transfer and parthenotes, due to limited and incorrect scientific facts available to the court at the time. The AG is of the opinion that the decisive criterion for assessing whether a human parthenote constitutes a ‘human embryo’ should be whether it is in fact functionally equivalent to a fertilized ovum, meaning whether it has the inherent capacity to develop into a viable human being.

In contrast to the Brüstle ruling, given the current understanding that human parthenotes lack the capacity to develop to term, the AG arrives at the conclusion that parthenotes should not be considered a ‘human embryo’. This assessment, however, is carefully qualified by the reservation that the parthenote has not been altered genetically so as to enable it to yet develop into a viable human being, an approach that already has been successfully applied in other species.

Implications

Provided that the CJEU follows the AG’s recommendation, as it does in the majority of cases, this ruling could provide some relief for applicants in the stem cell field. Specifically, it may open a way to patent protection for certain stem cell-related inventions by relying on pluripotent stem cells derived from parthenotes. At the same time, inventions based on conventional embryonic stem cells might not be patentable (see
LSIPR 2014, 1.3).

However, the AG also mentioned in his initial considerations that the practical effect of this decision might be limited by the non-exhaustive character of the list contained in Article 6(2) of the Biotech Directive. Any EU-member state could still exclude human parthenotes from patentability under the more general exclusion clause of Article 6(1) of the Biotech Directive, which excludes from patentability inventions whose commercial exploitation would be contrary to ordre public or morality.

As regards the EPO, one may expect that it will probably adapt its granting practice to this new CJEU case, as it has done previously in the aftermath of Brüstle (see EPO Guidelines 2013 G-II 5.3).
We protect and defend intellectual property – with the highest standards of legal and technical expertise as well as through close contacts with our clients. As one of the largest law firms in Europe dealing with the protection of intellectual property, we maintain a staff of over 400 employees. Among them, more than 90 patent attorneys and attorneys-at-law form specialized teams to provide expertise in all technical areas. And worldwide, we collaborate with legal partners in other countries.

**Munich Office**
Leopoldstr. 4
80802 Munich
Germany
Tel. +49 (0) 89 21 23 50
Fax +49 (0) 89 22 02 87

**Cologne Office**
Domkloster 1
50667 Cologne
Germany
Tel. +49 (0) 221 949 72 20
Fax +49 (0) 221 949 72 22

**Berlin Office**
Kurfürstendamm 38/39
10719 Berlin
Germany
Tel. +49 (0) 30 305 10 29
Fax +49 (0) 30 304 31 91

**Paris Office**
260 bvd Saint Germain
75007 Paris
France
Tel. + 33 (0) 1 80 40 02 60
Fax + 33 (0) 1 47 05 41 94

Email: info@grunecker.de
http://www.grunecker.de

---

**Contacting the Author**

**Munich Office**
Tel. +49 (0) 89 21 23 50
Email: zimmer@grunecker.de